Influence of phenylbutazone, mofebutazone and aspirin on the pharmacokinetics of dexamethasone in the rat
Tóm tắt
Phenylbutazone suppresses the C-6 hydroxylation, absorption rate, bioavailability, and renal and plasma clearance rates of dexamethasone administered orally to normal and oedemateous rats. It increases the half life and the volume of distribution. Aspirin exerts an effect which is less pronounced and involves the enhancement of the C-6 hydroxylation. Aspirin suppresses the half life and renal clearance of dexamethasone and enhances its hepatic clearance. Mofebutazone does not exert any pronounced influence. Also, unlike phenylbutazone, it does not interfere with the gastrointestinal absorption of dexamethasone. More rapid onset of absorption, decrease of half life and increase of the contribution of renal clearance to total plasma clearance of dexamethasone, are characteristics of the oedemateous condition in the rat. The constribution of renal clearance to the elimination of dexamethasone is much greater in the rat than in human subjects. The presence of a third unconjugated metabolite of dexamethasone in the urine of rat has been demonstrated.
Tài liệu tham khảo
Jubiz, W., Meikle, A.W., Levinson, R.A., Mizutani, S. West, C.D., and Tyler, F.H. (1970): Effect of diphenylhydantoin on the metabolism of dexamethasone. New England J. Med.,283, 11–14.
Haque, N., Thrasher, K., Werk, E.E.Jr., Knowls, H.C. Jr., and Sholiton, L.J. (1972): Studies on dexamethasone metabolism in man. J. Clin. Endocr. Metab.34, 44–50.
Rice, M.J., Tredger, J.M., Chakraborty, J., and Parke, D.V. (1974): The metabolism of dexamethasone in the rat. Biochem. Soc. Transactions2, 107–109 (1974).
English, J., Chakraborty, J., and Marks V. (1975): The metabolism of dexamethasone in the rat-effect of Phenytoin. J. of Steroid Biochem.6, 65–68.
Brooks, S.M., Sholiton, L.J., and Altenau, P. (1976): The effect of disodium cromoglycate on dexamethasone metabolism. Amer. Rev. Respir. Dis.114, 1191–1194.
Brooks, S.M., Werk, E.E., Ackerman, S.J., Sullivan, I., and Thrasher, K. (1972): Adverse effects of phenobarbital on corticosteroid metabolism in patients with bronchial astma. New Engl. J. Med.286, 1125–1128.
Hallbauer, F., and Heite, J.-J. (1959): Tierexperimentelle Untersuchungen zur „Retard”-Wirkung des Phenylbutazon auf verschiedene Corticosteroide. Med. Exp.1, 276–281.
Heiner, K.H., and Heite, H.-J. (1958): Zur Potenzierung der Hydrocortisonwirkung durch Phenylbutazon. Klin. Wschr.36, 370–372.
Norymberski, J.K., and Woods, G.F. (1955): Partial reduction of steroid hormones and related substances. J. Chem. Soc, 3426–3430.
Wagner, J.G. (1975): Fundamentals of clinical Pharmacokinetics. Drug Intelligence Publications, Inc., Hamilton, Illinois.
Havemann, D. (1977): Antiphlogistische Pharmaka. Untersuchungen zur Pharmacokinetik anti-inflammatorischer Substanzen. Fortschr. Med.95, 177–181.
Duggan, D.E., Yeh, K.C., Matalia, N., Ditzler, C.A. and McMahon, F.G. (1975): Bioavailability of oral dexamethasone. Clinical Pharmacol. Therapeutics18, 205–209.
Tsuei, S.E., Moore, R.G., Ashley, J.J., and McBride, W.G. (1979): Disposition of synthetic glucocorticoids. I. Pharmacokinetics of dexamethasone in healthy adults. J. Pharmacokin. Biopharm.7, 249–264.